NCT02059265 2023-08-01Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal CancerNational Cancer Institute (NCI)Phase 2 Terminated35 enrolled 13 charts